Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
Tolerability and Safety of HF1K16 Injection in Patients With Refractory Solid Tumors

HF1K16 is an investigational pegylated liposome formulation of All-Trans Retinoic Acid (ATRA) for the induction of remission in patients with acute promyelocytic leukemia (APL) and for the

  • 0 views
  • 05 Jun, 2022
  • 3 locations
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RAR transcript and less than 18 years of age.

  • 0 views
  • 21 Mar, 2021
  • 29 locations
Study for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia (TUD-APOLLO-064)

Acute promyelocytic leukemia (APL) is a rare subtype of acute myeloid leukemia (AML) characterized by consistent clinical, morphologic, and genetic features. According to the FAB classification

myeloid leukemia
secondary mds
idarubicin
anthracyclines
mitoxantrone
  • 0 views
  • 07 Apr, 2022
  • 7 locations
AIDA 2000 Guidelines

Prospective use of RT-PCR for PML/RARa might be used to guide a total tehrapy approach in APL, including refined diagnosis, front-line treatment, assessment of response and anticipated salvage therapy for patients who undergo molecular relapse.

serum bilirubin level
tretinoin
serum bilirubin
  • 42 views
  • 27 Feb, 2022
  • 2 locations
A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients 60 Years Old

The study will include newly-diagnosed AML patients, not suffering acute promyelocytic leukemia; aged 18-60 years, who are eligible for standard induction chemotherapy. The patients will be

induction chemotherapy
secondary acute myeloid leukemia
cell transplantation
decitabine
blast cells
  • 32 views
  • 07 Oct, 2021
  • 10 locations
Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF) (APL16)

The investigators design a multicenter randomized controlled trial to prove that RIF plus ATRA is possibly superior to ATO plus ATRA as consolidation and maintenance treatment for the patients with non-high-risk APL.

acute promyelocytic leukemia
maintenance treatment
hydroxyurea
tretinoin
arsenic
  • 15 views
  • 23 Feb, 2022
  • 1 location
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

SY-2101 is being studied as a treatment for participants with a type of leukemia called acute promyelocytic leukemia (APL). SY-2101 is an oral form of a drug called arsenic trioxide (ATO). ATO

acute promyelocytic leukemia
remission
consolidation therapy
cancer
  • 0 views
  • 13 Mar, 2022
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia. Drugs

gemtuzumab ozogamicin
idarubicin
cancer
serum pregnancy test
PCR test
  • 26 views
  • 30 May, 2022
  • 5 locations
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia

Acute promyelocytic leukemia (APL) is characterized by t(15;17)(q24;21) and the fusion gene PML-RARA. We have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is

acute promyelocytic leukemia
tretinoin
arsenic
  • 18 views
  • 12 Feb, 2022
Frontline Oral Arsenic Trioxide for APL

The investigators have formulated an oral preparation of As2O3 (oral-As2O3), and shown that it is efficacious for APL in R1, inducing CR2 in more than 90% of patients [8,9]. Furthermore, in an effort to prevent relapse, the investigators have moved oral-As2O3 forward to the maintenance of CR1. This strategy results …

  • 0 views
  • 27 Jan, 2021
  • 1 location